GlycoMimetics To Host Leader Event To Review Results From Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia On June 4, 2024
GlycoMimetics To Host Leader Event To Review Results From Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia On June 4, 2024
GlycoMimetics, Inc. (NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company's pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML).
GlycoMimetics, Inc.（納斯達克股票代碼：GLYC）是一家處於臨床後期階段的生物技術公司，正在發現和開發基於糖生物學的癌症和炎症性疾病療法。該公司今天宣佈，它將在美國東部時間2024年6月4日星期二上午 8:30 舉辦一次重要的意見領袖活動，全面概述該公司對復發/難治性（R/R）的Uproleselan的關鍵性3期研究的數據髓系白血病（AML）。
The event will feature the study's principal investigator Daniel DeAngelo, M.D., Ph.D., Professor of Medicine, Harvard Medical School, and Chief of the Division of Leukemia, Dana-Farber Cancer Institute, who will discuss results from the pivotal Phase 3 study of uproleselan, along with the current AML treatment landscape and unmet patient need.
該研究的首席研究員丹尼爾·迪安傑洛（Daniel DeAngelo），醫學博士，哈佛醫學院醫學教授和達納-法伯癌症研究所白血病科主任，他們將討論uproleselan的關鍵3期研究的結果，以及當前的急性髓細胞白血病治療格局和未滿足的患者需求。
To access the event by phone, please go to this registration link to obtain the dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time.
要通過電話訪問活動，請訪問此註冊鏈接以獲取撥號的詳細信息。鼓勵參與者在預定開始時間前 15 分鐘進行連接。
A live webcast of the call will be available on the "Investors" tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call.
電話會議的網絡直播將在GlycoMimetics網站的 “投資者” 選項卡上播出。電話會議結束後的30天內將提供網絡直播重播。